Funding for this research was provided by:
Ministry of Science, ICT and Future Planning (2018R1A2A2A15023219)
Ministry of Health and Welfare (HI20C0253)
Medical Research Center (2017R1A5A2015395)
GemVax and KAEL
Received: 16 November 2020
Accepted: 8 March 2021
First Online: 26 March 2021
: The study protocol was approved by the independent institutional review boards of each participating center. The process was performed according to Good Clinical Practice guidelines. All participants provided written informed consent.
: Not applicable
: KSJ is an employer of GemVax & Kael Co., Ltd. and holds equity in the company. Other authors declare no competing interests.